Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Pancreatic Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 67Radiotherapy 53Cisplatin 52Oxaliplatin 47Leucovorin 37Paclitaxel 36Irinotecan 27Docetaxel 23Capecitabine 20Nivolumab 17Carboplatin 16pembrolizumab 15Radiation 15Neoadjuvant Therapy 15Surgical Procedures, Operative 12Cetuximab 12durvalumab 9Drug Therapy 9Biopsy 9Taxes 8Folfox protocol 8Chemotherapy, Adjuvant 8Trastuzumab 7Magnetic Resonance Spectroscopy 7Gefitinib 7Endoscopy 7tremelimumab 6Specimen Handling 6Endoscopy, Digestive System 6Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × vandetanib × Gastrointestinal × Clear all
NCT00732745 2011-08-22

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Case Comprehensive Cancer Center

Phase 1 Terminated
9 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡